VistaGen Therapeutics Q2 2024 EPS $(0.66) Beats $(0.68) Estimate, Sales $277.70K Beat $180.00K Estimate
Portfolio Pulse from totan@benzinga.com
VistaGen Therapeutics reported Q2 2024 earnings per share (EPS) of $(0.66), beating the analyst consensus estimate of $(0.68) by 2.94%. This is a 72.5% increase over the same period last year. The company also reported quarterly sales of $277.70K, beating the analyst consensus estimate of $180.00K by 54.28%, a 131.11% increase over the same period last year.
November 09, 2023 | 9:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
VistaGen Therapeutics reported better than expected Q2 2024 earnings and sales, which could positively impact the stock in the short term.
VistaGen Therapeutics reported better than expected earnings and sales for Q2 2024. This positive financial performance could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100